Clinical trials: Refractory and/or Relapsed Metastatic Solid Tumors
Solid Tumor, Adult, Lymphoma
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
This is a pilot clinical trial for subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas to determine the safety, efficacy and immune response of autologous EphA2-targeting CAR-DC vaccine…
- Conditions
- Solid Tumor, Adult, Lymphoma, EphA2 Overexpression, TP53 R273H
- Trial name
- NCT05631886
- Testing
- TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Cancer
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended…
- Trial name
- NCT05040932
- Testing
- YH004
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Brain Tumor, Central Nervous System Tumors
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and…
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia
- Trial name
- NCT00066248
- Testing
- cyproheptadine hydrochloride, megestrol acetate
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- University of South Florida
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Solid Tumor
Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to evaluate the safety, tolerability, and PK of IGM-7354 in participants with relapsed and/or refractory tumors.
- Trial name
- NCT05702424
- Testing
- IGM-7354
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- IGM Biosciences, Inc.
Chronic Myeloproliferative Disorders, Leukemia
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of decitabine in treating patients with stage III or stage…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00002980
- Testing
- decitabine
- Where
- 4 sites in United States
- Sponsor
- California Cancer Consortium
Advanced Cancer, Metastatic Cancer
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
This first-in-human open-label, dose escalation study is designed to evaluate the safety, tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or metastatic solid tumors.
- Conditions
- Advanced Cancer, Metastatic Cancer, Neoplasms, Neoplasm Metastasis
- Trial name
- NCT03510104
- Testing
- MRX-2843
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Meryx, Inc.
Advanced Solid Tumors
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
- Trial name
- NCT05533697
- Testing
- mRNA-4359, Pembrolizumab, Ipilimumab
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 361 people
- Sponsor
- ModernaTX, Inc.
Refractory and/or Relapsed Metastatic Solid Tumors
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk…
- Trial name
- NCT01804634
- Testing
- Cyclophosphamide, Fludarabine, low dose total body irradiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasm Metastasis
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies.
- Trial name
- NCT02677116
- Testing
- Olaratumab, Doxorubicin, Vincristine
- Where
- 21 sites in United States, Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC)…
- Conditions
- Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05274451
- Testing
- LYL797
- Where
- 18 sites in United States
- Volunteers
- 57 people
- Sponsor
- Lyell Immunopharma, Inc.
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions in mismatch-repair proficient (MSS) colorectal cancer.
- Trial name
- NCT03711058
- Testing
- Copanlisib, Nivolumab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate LYL845 in Adults With Solid Tumors
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05573035
- Testing
- LYL845
- Where
- 18 sites in United States
- Volunteers
- 39 people
- Sponsor
- Lyell Immunopharma, Inc.
Solid Tumor, Lymphoma
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas
The potency of immune checkpoint blockade is limited in most solid malignancies, one possible reason for which is tumor microenvironment.
- Trial name
- NCT04407741
- Testing
- SHR2554+SHR1701, SHR1701
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Breast Cancer, Chronic Myeloproliferative Disorders
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003107
- Testing
- recombinant interleukin-12
- Where
- United States
- Sponsor
- Indiana University
Solid Tumor, Lymphoma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the…
- Trial name
- NCT03884556
- Testing
- TTX-030, Pembrolizumab, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- Trishula Therapeutics, Inc.
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin's…
- Trial name
- NCT04606433
- Testing
- GNC-038
- Where
- 10 sites in China
- Volunteers
- 47 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in treating young patients with relapsed or refractory solid tumors or leukemia.
- Conditions
- Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Trial name
- NCT00079404
- Testing
- tanespimycin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)